What precision measures matter to patients? Can we use these to differentiate our portfolio and bring better, patient-centered treatments to market faster?
What assessments, including COAs and non-digital biomarkers, should we include in our protocol to make clinical research more effective?
How can we eliminate the risk of poor measurement selection or incomplete data to bring treatments to market faster and improve the lives of patients?
We harness the evidence of AI-powered digital biomarkers and eCOAs to help biopharma accelerate patient-centered clinical research
All evidence in our platform meets predefined quality metrics. For example:
The platform enables more efficient, evidence based decisions on measures and tools and greater confidence in downstream use in a study or care management